Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

Schizophrenia Research
Julio BobesEIRE Study Group

Abstract

The aim of this cross-sectional study, the EIRE study, was to assess the frequency of several side effects with antipsychotics in the clinical setting. This paper addresses the adverse effect of weight gain. Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited. Data were collected in a single visit, including data on demographic, clinical and treatment characteristics. Mean weight change was evaluated retrospectively by means of clinical charts and the weight at the time of the visit; in addition, the corresponding item of a modified version of the UKU, a Scandinavian side-effect rating scale, was used. Chi-squared test and logistic regression methods were used to analyze frequency of weight gain between treatments. Out of 669 recruited, 636 evaluable patients were assessed. The treatment with the highest number of patients with weight gain as an adverse reaction on the UKU scale was olanzapine (74.5%), followed by risperidone (53.4%) and haloperidol (40.0%). The proportion of patients with clinically relevant weight gain (>or=7% increase versus initial weight) was also highe...Continue Reading

References

Mar 1, 1992·Journal of Behavior Therapy and Experimental Psychiatry·D PavalonisM Downs
Jan 1, 1992·The American Journal of Psychiatry·R LeadbetterM Downs
Jan 1, 1991·Journal of Clinical Epidemiology·A RissanenJ Maatela
Aug 31, 1989·The New England Journal of Medicine·K M MaclureW C Willett
Jan 16, 1987·JAMA : the Journal of the American Medical Association·J E MansonW C Willett
Feb 1, 1984·Annals of Internal Medicine·A P Simopoulos, T B Van Itallie
Sep 14, 1995·The New England Journal of Medicine·J E MansonF E Speizer
Feb 8, 1995·JAMA : the Journal of the American Medical Association·W C WillettC H Hennekens
Apr 1, 1995·Annals of Internal Medicine·G A ColditzJ E Manson
May 1, 1996·The British Journal of Psychiatry. Supplement·S R HirschL A Arvanitis
Jan 1, 1996·Comprehensive Psychiatry·S MukherjeeP L Scapicchio
Nov 14, 1997·Acta Psychiatrica Scandinavica·J Peuskens, C G Link
Jan 24, 1998·Annals of Internal Medicine·Z HuangG A Colditz
Apr 30, 1999·The Journal of Clinical Psychiatry·D B AllisonL J Cheskin
Sep 2, 1999·Stroke; a Journal of Cerebral Circulation·H IsoW C Willett
Oct 3, 1999·Journal of Clinical Psychopharmacology·W W Fleischhacker, M Hummer
Feb 9, 2000·The Journal of Clinical Psychiatry·R M HirschfeldJ M Russell
Aug 11, 2000·General Hospital Psychiatry·A I GreenG Blackburn
Feb 24, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T Wetterling

❮ Previous
Next ❯

Citations

Jun 15, 2006·Der Nervenarzt·T Attarbaschi, S Kasper
Nov 29, 2005·Clinical Neurology and Neurosurgery·Yeşim YetimalarMustafa Başoğlu
Jul 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Peter J WeidenHarold E Lebovitz
May 11, 2006·The Australian and New Zealand Journal of Psychiatry·Chul LeePhil Lee
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Sep 19, 2009·Pharmacogenomics·Sara HaackJulia Kirchheiner
Sep 17, 2008·Srpski arhiv za celokupno lekarstvo·Nadja MarićMiroslava Jasović-Gasić
Jul 5, 2013·Preventing Chronic Disease·Maria RomanovaDavid Heber
Jan 1, 2011·Schizophrenia Research and Treatment·Fabio PanarielloAndrea de Bartolomeis
Feb 4, 2010·Neuroscience·J Sánchez-WandelmerR Busto
Sep 29, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·M BernardoUNKNOWN RICAVA Study Group
Mar 8, 2011·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc DE HertStefan Leucht
Apr 21, 2004·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·T LobsteinUNKNOWN IASO International Obesity TaskForce
May 23, 2009·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·S Gentile
May 26, 2006·Expert Opinion on Pharmacotherapy·Michael KrebsMartin Schaefer
Nov 3, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·J BobesUNKNOWN CLAMORS Study Collaborative Group
Sep 1, 2005·Current Therapeutic Research, Clinical and Experimental·Gordon G LiuZhongyun Zhao
Jun 23, 2016·Journal of Basic and Clinical Pharmacy·Sathvik Belagodu SridharRiadh Jabbar
Mar 2, 2016·Revista de psiquiatrí́a y salud mental·Ángel L MontejoEduard Vieta
Jan 19, 2010·Psychiatry Research·Konstantinos N FountoulakisSymeon Deres
Feb 4, 2014·Therapeutic Advances in Psychopharmacology·Marina Salviato BalbãoRegina Helena Costa Queiroz
Mar 30, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Salvatore Gentile
Sep 17, 2008·Journal of Clinical Psychopharmacology·Chee Kok Yoon
Apr 20, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·George LiamisMoses Elisaf
Jan 17, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M B CopeT R Nagy
Feb 3, 2006·The New England Journal of Medicine·John M Davis
Jul 13, 2006·Expert Review of Neurotherapeutics·Chanoch Miodownik, Vladimir Lerner
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Adib EssaliJohn Rathbone
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Psychiatric Services : a Journal of the American Psychiatric Association
John M DavisIra D Glick
© 2022 Meta ULC. All rights reserved